IFS Group’s AbbVie ABBV Stock Holding History

IFS Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,647	Closed	-$358K	–	88
2026 Q1	$358K	Buy	+1,647	New	+$365K	0.32%	89
2025 Q3	$411K	Buy	+1,682	New	+$343K	0.36%	75

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

IFS Group's ABBV Position: Q2 2026 in Review

IFS Group sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 1,647 shares — an estimated $358K sold.

IFS Group first reported a position in ABBV in Q3 2025 and held it in 2 quarters. The position peaked at $411K in Q3 2025. 4,209 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

IFS Group reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
IFS Group sold 1,647 AbbVie shares in Q2 2026, an estimated $358K.
IFS Group first reported a position in AbbVie in Q3 2025 and held it in 2 quarters.
IFS Group's AbbVie position peaked at $411K in Q3 2025.
4,209 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on IFS Group's 13F filing for Q2 2026, filed 23 Jul 2026.